These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 9113619)

  • 41. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z; Bachelot A; Samara-Boustani D; Ruiz JC; Donadille B; Dulon J; Christin-Maître S; Bouvattier C; Raux-Demay MC; Bouchard P; Carel JC; Leger J; Kuttenn F; Polak M; Touraine P;
    Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia.
    Merke DP; Keil MF; Jones JV; Fields J; Hill S; Cutler GB
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1114-20. PubMed ID: 10720048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adult height of subjects with nonclassical 21-hydroxylase deficiency.
    Eyal O; Tenenbaum-Rakover Y; Shalitin S; Israel S; Weintrob N
    Acta Paediatr; 2013 Apr; 102(4):419-23. PubMed ID: 23298233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Are short boys disadvantaged as adults? Follow-up of 77 men with constitutional growth delay and (or) familial short stature].
    Holl RW; Schröder H; Heinze E
    Dtsch Med Wochenschr; 1991 Jun; 116(24):928-34. PubMed ID: 2044460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort.
    Sarafoglou K; Addo OY; Turcotte L; Otten N; Wickremasinghe A; Pittock S; Kyllo J; Lteif AN; Himes JH; Miller BS
    J Pediatr; 2014 May; 164(5):1141-1146.e1. PubMed ID: 24560184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood.
    Yu AC; Grant DB
    Acta Paediatr; 1995 Aug; 84(8):899-903. PubMed ID: 7488814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management.
    Pinto G; Tardy V; Trivin C; Thalassinos C; Lortat-Jacob S; Nihoul-Fékété C; Morel Y; Brauner R
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2624-33. PubMed ID: 12788866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.
    Gussinyé M; Carrascosa A; Potau N; Enrubia M; Vicens-Calvet E; Ibáñez L; Yeste D
    Pediatrics; 1997 Oct; 100(4):671-4. PubMed ID: 9310523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial high dose hydrocortisone (HDC) treatment for 21-hydroxylase deficiency (21-OHD) does not affect linear growth during the first three years of life.
    Takasawa K; Ono M; Miyai K; Matsubara Y; Takizawa F; Onishi T; Kashimada K; Mizutani S
    Endocr J; 2012; 59(11):1001-6. PubMed ID: 22785554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism.
    Cordeiro GV; Silva IN; Goulart EM; Chagas AJ; Kater CE
    Arq Bras Endocrinol Metabol; 2013 Mar; 57(2):126-31. PubMed ID: 23525290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Dörr HG
    Horm Res; 2007; 68 Suppl 5():93-9. PubMed ID: 18174719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty.
    Charmandari E; Hindmarsh PC; Johnston A; Brook CG
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2701-8. PubMed ID: 11397874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
    Juan L; Huamei M; Zhe S; Yanhong L; Hongshan C; Qiuli C; Jun Z; Song G; Minlian D
    J Pediatr Endocrinol Metab; 2016 Jul; 29(7):841-8. PubMed ID: 27054598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia.
    Lin-Su K; Vogiatzi MG; Marshall I; Harbison MD; Macapagal MC; Betensky B; Tansil S; New MI
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3318-25. PubMed ID: 15797962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
    Leite FM; Longui CA; Kochi C; Faria CD; Borghi M; Calliari LE; Monte O
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):101-8. PubMed ID: 18345402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature.
    Crowe BJ; Rekers-Mombarg LT; Robling K; Wolka AM; Cutler GB; Wit JM;
    J Clin Endocrinol Metab; 2006 Jan; 91(1):169-75. PubMed ID: 16263828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
    Zimmermann A; Sido PG; Schulze E; Al Khzouz C; Lazea C; Coldea C; Weber MM
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Growth in disorders of adrenal hyperfunction.
    Savage MO; Scommegna S; Carroll PV; Ho JT; Monson JP; Besser GM; Grossman AB
    Horm Res; 2002; 58 Suppl 1():39-43. PubMed ID: 12373013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overestimation of final height prediction in patients with classical congenital adrenal hyperplasia using the Bayley and Pinneau method.
    Bonfig W; Schwarz HP
    J Pediatr Endocrinol Metab; 2012; 25(7-8):645-9. PubMed ID: 23155688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Final height and pubertal development in children with growth hormone deficiency after long-term treatment.
    Frisch H; Birnbacher R
    Horm Res; 1995; 43(4):132-4. PubMed ID: 7750913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.